To the Editor In a secondary analysis of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source trial, Healey and colleagues¹ determined that for patients with embolic stroke of undetermined source and left atrial enlargement rivaroxaban treatment was associated with a 74% reduction in recurrent stroke.¹ The authors suggest that left atrial enlargement could become a new determinant in secondary stroke prevention.

中文翻译：

---

在初步的卒中评估中，可以在扩展的计算机断层扫描血管造影上检测到左心房扩大。

致编辑在对新方法的利伐沙班抑制Xa因子在ASA预防未确定来源的栓塞性中风栓塞的新方法的辅助分析中，Healey及其同事¹确定了对于来源不确定且左心房栓塞性中风的患者利伐沙班扩大治疗与复发性中风减少74％有关。¹作者认为，左心房扩大可能成为继发性中风预防的新决定因素。